An update on the pharmacotherapeutic management of lower respiratory tract infections

Mario Cazzola, Paola Rogliani, Stefano Aliberti, Francesco Blasi, Maria Gabriella Matera

Research output: Contribution to journalReview article

Abstract

Introduction: Our knowledge about lower respiratory tract infections (LRTIs) has improved substantially in the last years, but the management of respiratory infections is still a challenge and we are still far from using precision medicine in their treatment. Areas covered: The approaches developed in recent years to improve the pharmacotherapeutic management of LRTIs, such as novel diagnostic assays to facilitate medical decision-making, attempts for selecting an optimal empiric antibiotic regimen, and the role of new and possibly unproven adjunctive therapies, are described. Expert opinion: Early and appropriate antibiotics remain the cornerstone in the treatment of LRTIs. The updated trend is to apply antimicrobial stewardship principles and initiatives to optimize both the management and the outcomes of LTRIs. Biomarkers, mainly C-reactive protein (CRP) and procalcitonin (PCT), can improve the diagnostic and prognostic assessment of LRTIs and aid to guide antibiotic therapy. The widespread use of antimicrobial agents has greatly contributed to faster development of antibiotic resistance and the emergence of opportunistic pathogens, which substitute the indigenous microbiota. However, very few new antibiotics in development to overcome existing resistance and ensure continued success in the treatment of LRTIs have been approved, likely because antibiotic stewardship programs discourage the use of new agents.

Original languageEnglish
Pages (from-to)973-988
Number of pages16
JournalExpert Opinion on Pharmacotherapy
Volume18
Issue number10
DOIs
Publication statusPublished - Jul 3 2017

    Fingerprint

Keywords

  • Adjuvant therapies
  • antibiotic regimen
  • biomarkers
  • bronchiectasis
  • community-acquired pneumonia
  • COPD exacerbation
  • guidelines
  • hospital acquired pneumonia
  • lower respiratory tract infections
  • novel antibiotics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this